The CCR8 inhibitor (ML604086) developed by MedImmune (Gaithersburg, MD, USA) was previously developed with the aim to treat asthma marked by infiltration of a high number of eosinophils and Th2 cells responsible for the disease [318]. The gene discussed is CCR8; the disease is asthma.